

The Impact of a Private Supplement to Public Health Care: The Mexico Diabetes Experiment *

Ari Bronsoler

MIT

Jonathan Gruber

MIT and NBER

Enrique Seira

ITAM and JPAL

First draft: April 2021

This draft: April 1, 2021

Abstract

There are ongoing debates around the world over the value of private supplements to public health insurance systems. We investigate this issue in the context of one of the world's deadliest diseases, diabetes, and one of the countries with the worst diabetes problems in the world, Mexico. We implement a novel deniers randomization approach to cost-effectively provide a causal estimate of enrollment in private supplement to the free public health system. Our final sample of more than 1000 diabetics randomized into a large price subsidy for enrollment in the private plan is well balanced. We estimate enormous impacts of the private supplement, with blood sugar levels falling by a full point (relative to a control mean of 8.5%), and to increase the share of those treated who are under control by 69%. We show that this effect arises through both improved treatment compliance and health behaviors, and that diabetes complications fall even in the short run. The net costs of this intervention are at most one-third of the gross costs due to offsetting public sector savings, and the health benefits are many multiples of gross costs. But the returns to private care do not appear to reflect more productive delivery of care per visit, which is comparable in a separate quasi-experimental analysis of public insurance; rather, affects arise through more attachment to medical care in the private alternative.

Keywords: Health, Diabetes, Mexico.

*We are grateful to Eduardo Rivera for outstanding research assistance and to Dante Salazar for impressive field coordination. We also want to thank Diego del Pilar for his contributions as well as participants in the development and public finance lunches at MIT. We also want to thank Clinicas del Azucar for being an amazing partner and the Lilly Global Health Initiative for supporting this project.

1 Introduction

Most countries of the world feature universal or near universal public provision of either health insurance, or direct health care, to residents. And in all of these countries, this public provision is to some extent supplemented by private options, such as private insurance products or private health care providers. A common feature of all nations with such mixed public-private systems is dissatisfaction with the current mix. Regardless of the relative size of the private alternative, advocates and opponents of privatization argue for a larger or smaller public sector role.

A classic example is the debate in the U.S. over allowing Veterans to access private providers outside of the Veterans' Affairs system, as well as debates in the U.K. over tendering of private contracts for their National Health System (see the discussion in [Frakes et al. \(2021\)](#)). This debate extends to the developing world as well. For example, a plan by the economist running Mexico's largest social insurance institution to test privatized medical services was strongly opposed by the unionized public sector doctors and ultimately shut down.¹

In this paper, we investigate this set of issues in the context of one of the most important public health issues facing developing countries: diabetes. After decades of being primarily concerned with undernutrition around the world, policy makers are shifting their focus to this new problem that arises from both improper eating and overconsumption. There were 4.2 million deaths due to diabetes complications in 2019. Worldwide prevalence rates have risen from 4.7% in 1980 to 9.3% in 2019 and the increase has been most rapid for developing nations; the rate of diabetes is now higher in low-income nations than in high-income nations. ([Saeedi et al., 2019](#)).

We focus on Mexico, one of the nations hardest hit by the growth in diabetes. Diabetes prevalence has risen from 6.7% in 1994 to 11% in 2018, and, signaling poor control, the country has almost twice the mean diabetic hospital admission rate among the OECD countries. The estimated costs of addressing diabetes and its complications are 2.25% of GDP, and diabetes spending represents 10% of the entire budget of the Ministry of Health. However, when uncontrolled, diabetes often leads to dire consequences. In Mexico, the disease is the second most common cause of death and is among the top 5 causes of disability ([OECD, 2019](#); [Barraza-Lloréns et al., 2015](#); [INEGI, 2019b](#); [INSP, 2018](#)).

¹See [almomento.mx \(2015\)](#)

The primary approach taken by Mexico to address the health consequences of diabetes is through its public health systems, the largest of which covers 70.3 million formal sector workers and their families in the nation and serves 4.7 million diabetics per year (IMSS, 2020, 2018a). Yet there is widespread dissatisfaction with this care; 22% of those who used the public sector would not return for future care if given a choice and under a quarter rate the service as very good (INSP, 2018). As the result of large waiting times², a nascent private sector has emerged to provide complementary primary care. The share of private medical offices went from 5% in 1990 to over 30% in 2020. In 2018, nearly 20% of diabetics reported getting treatment on private institutions (INSP, 2018; SSP, 2021).

Given the enormous human and fiscal costs of this disease for Mexico, understanding the implications of these private alternatives for the costs and consequences of diabetes in the nation is paramount. Yet evaluating the impact of private alternatives faces a number of challenges. Use of private alternatives is endogenous, and randomized trials are very difficult due to recruitment challenges and the enormous sample needed to obtain sufficient first stage power. As a result, neither in Mexico nor in other middle and lower-income countries, do we have well-identified estimates of the impact of private treatment for disease.

In this paper, we implement a novel *deniers randomization* approach to cost-effectively provide a causal estimate of enrollment in private diabetes care. We run this experiment in partnership with a private provider of comprehensive diabetes care in Mexico, Clinicas de Azucar (CdA). CdA runs a chain of clinics that provide a wide range of services to diabetics, ranging from blood sugar measurement to medical interventions to nutritional counseling. This service is fairly expensive, at a cost of 7000 Pesos (\$350 USD) per year, or 5% of median Mexican family yearly income, at the time of our experiment.³

Our initial sample is individuals who undergo a free initial comprehensive diabetes evaluation at CdA, which we randomize into treatment and control groups and survey at baseline. After their evaluation, these individuals are offered the opportunity to enroll in CdA at full-price, and 60% do so. Among those who decline, an additional opportunity to enroll at 40% of the baseline price

²IMSS has an average of 1 hour of 15 minutes in waiting times while private sector has only a 20 minutes wait (INSP, 2018).

³Estimation based on monthly earnings from the 5th decile in the distribution in INEGI (2018). The cost of CdA has risen recently to 8000 Pesos.

is presented to treatments but not controls. The rate of use among those offered this discount is 49%, compared to a 21% ultimate rate of enrollment for the control group that does not get this offer (but may receive subsequent marketing from CdA). This provides a powerful first stage to investigate the impact of CdA treatment in a cost-effective way.

Our follow up surveys and biometric measurement were scheduled for May, 2020, making us one of the many randomized trials adversely impacted by COVID-19. But due to aggressive use of PPE and other protocols, our follow up was delayed by only 4 weeks. Our follow up rate of data collection of 45% was below expectations, but provided a sufficiently large sample to powerfully investigate the impact of the CdA treatment; moreover, the sample appears balanced along all measurable dimensions and we see no evidence of differential attrition.

Using this approach, we find a striking positive effect of the CdA intervention: the implied effect of participation is to lower blood sugar levels (measured by glycated hemoglobin or HbA1c) by a full point (relative to a control mean of 8.5%), and to increase the share of those treated who are under control by 69%. This is a huge impact, which according to the widely cited UKPDS study, could reduce microvascular diabetes complications by 35%. Moreover, this impact is at the upper end of estimated effect sizes from other diabetes interventions reviewed in a recent meta-analysis ([Pimouguet et al., 2011a](#)).

We show that this effect arises through a number of changes to behavior, including greater compliance with recommended medications and substitution for less effective and more invasive treatments; some change in behavior such as exercise and diet, and importantly more frequent visits to medical providers. We find that diabetic complications fall, even in the short run. We also find significant heterogeneity, with those who have worst baseline blood sugar control seeing the largest benefit.

To consider further the welfare implications of our results, we then extend them in two ways. First, we explore the cost effectiveness of the CdA intervention. The net costs of this intervention are much lower than the gross costs because of savings to the public health system. Some of these savings arise from reduced use of public primary care. But the larger source of savings is the direct positive fiscal externality from improved private care in terms of reduced (publicly paid) hospital spending. Adding these components, we estimate that the net costs of this private supplement is only 1/3 of its gross costs. At the same time, our estimated health benefits are on the order of 3-6

times the gross costs of the private program.

Second, we assess whether these returns to private care reflect a more productive delivery of care per visit or simply more quantity of care that is delivered equally effectively. We use data from the major public sector insurer (IMSS), along with variation coming from the distance to public clinics, to estimate the marginal returns per visit to IMSS diabetes care. We find that, after controlling for differential observable selection into private sector care, the returns to public and private care per visit are in fact comparable. This suggests that the returns from CdA reflect the ability of the private vendor to encourage more care. We confirm this conclusion by showing that our treatment effects are in fact highest where public clinics are most crowded.

Taken together, our findings suggest that private delivery of diabetes care had major benefits in Mexico. It led to improved health and significant offsets to public sector hospital expenditures, and at standard values of improved health was highly cost effective. But the source of the improvements was not necessarily better technology for diabetes care, but rather encouraging more care. This suggests multiple paths forward for governments seeking to improve their diabetes care, ranging from outsourcing care, to improving the attractiveness of the public option. Our paper also introduces a new cost-effective approach to randomization in evaluating private alternatives for public services delivery.

Our findings contribute to the long-standing discussion on public vs private healthcare provision. In a systematic review of the literature, [Basu et al. \(2012\)](#) document that the private sector is usually not more efficient, accountable, or medically effective than the public sector but offers better waiting times and hospitality towards patients. [Das et al. \(2012\)](#) and [Das et al. \(2016\)](#) document through standardized patient comparisons in India that both the public and private sector offer similar (low) quality services, with public sector physicians being more prepared but private sector practitioners compensating with more effort per appointment. We contribute to this literature by showing that there is a large health benefit of adding a (subsidized) private option, even for those with free public healthcare, and even if the private option is not necessarily of higher quality per unit of delivery. This is especially true in a context where public healthcare is overstretched. Second, we run one of the largest double-blind diabetes experiments in the normal field circumstances, and show that standard diabetes care with simple and cheap technology can have an enormous impact on reaching normal sugar levels, which means that the next relevant question

is how to attract people and keep them engaged with treatment. Meta reviews of different kind of interventions can be found in [Ismail et al. \(2004\)](#), [Umpierre et al. \(2011\)](#), [Ajala et al. \(2013\)](#) and [Pimouguet et al. \(2011b\)](#) Finally, we show that large fiscal externalities pay many-fold for the subsidy we implemented, contributing to the literature on fiscal externalities from health interventions. See literature discussion in [Chandra et al. \(2010\)](#)

Our paper proceeds as follows. Section 2 provides background on diabetes in general and in Mexican context, on the Mexican public health care system, and on the role of private alternatives such as CdA. Section 3 describes CdA and the design of the Mexico Diabetes Experiment. Section 4 presents our basic results on outcomes, mechanisms, and heterogeneity. Section 5 estimates the spillovers onto the public sector and the total social value of the improved care. Section 6 then explores the relative efficacy of public and private sector care. Section 7 concludes.

2 Diabetes and the Mexican Health Care Context

Over the past 25 years, one of the fastest growing public health problems around the world has been diabetes. Diabetes is a progressive and often-fatal disease with no known cure. It can attack every organ in the body, resulting in higher risk of heart failure, stroke and poor circulation, which can lead to amputation of extremities, kidney failure, retinopathy and death. Those with Type I diabetes don't produce insulin, which turns glucose (sugar) into energy; those with Type II diabetes don't respond to insulin appropriately and don't make sufficient amounts of insulin. Worldwide, 463 million people are estimated to have diabetes.

While diabetes cannot currently be cured, it can be brought under control by following diet and exercise recommendations, closely monitoring blood sugar levels, and adjusting prescriptions accordingly.⁴ Unlike several other chronic illnesses such as AIDS or Hepatitis C, diabetes can be easily and cheaply managed with relatively inexpensive medicine; Metformin, which is the most common pill used to control early-stage diabetes, costs under 2 dollars/month.⁵

The gold standard for measuring diabetes status is glycated hemoglobin (HbA1c). A hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin, the part of red blood cells that carries oxygen from lungs to the rest of the body. An HbA1c test shows what

⁴[Saeedi et al. \(2019\)](#) and [IDF \(2019\)](#).

⁵[Clinic \(2020\)](#).

the average amount of glucose attached to hemoglobin has been over the past three months; a three month average is used because that's typically how long a red blood cell lives. Individuals are diagnosed as diabetic with an HbA1c level of over 6.5% and diabetic patients are recommended to keep their levels below 7% (NIDDK, 2018). A more accessible and easier to use instrument to monitor blood sugar is the glucometer, which captures the blood sugar levels at any one point in time. While this measure has significantly more variance than HbA1c, it does not require lab processing and patients can use it in the privacy of their own home. Normal levels for this measurement are under 100 mm/hg and a patient will be diagnosed if she gets two fasting measurements over 125 (WHO, 2021).

Health care in Mexico is provided primarily by several public sector institutions. The largest is Instituto Mexicano del Seguro Social (IMSS), the single payer insurance plan for formal sector workers in the country. This program covers formal workers and their families as well as students but also offers a voluntary enrollment option which makes up under 1% of beneficiaries. Every private employer that hires a new employee is required to enroll him/her to IMSS. This service is paid for in 3 parts: On average, the government contributes 5.3% of employees base wages, employers contribute 16.5% and employees another 2.5%.⁶ IMSS runs its own 1522 primary care clinics, 248 acute care hospitals, and 61 specialty hospitals (IMSS, 2018b). Smaller but similar public options for particular sectors such as government workers (ISTEE), the navy (SEMAR), the army (SEDENA), and for workers of the state-owned oil company (PEMEX).

In 2003, Mexico introduced a new program, Seguro Popular, to extend health care coverage to informal workers. This program recently changed its name to the wellness institute (INSABI) and currently covers 60 million people, although everyone is eligible to enroll (SSP, 2018). While this service expansion benefits workers in the informal sector, survey evidence shows that Mexicans prefer other options.⁷ Today, 83% of the population reports being affiliated to one of these systems, with 45% at formal sector systems, 38% at INSABI, and 0.6% holding private insurance. Total health care spending in Mexico is 5.6% of GDP (INEGI, 2017, 2019a).

Despite the availability of free public health care, diabetes remains a major problem in Mexico.

⁶Law of Social Security.

⁷Based on data from the health and nutrition survey in 2018 that asks about satisfaction with a service. Data shows that the following percentage of patients believe the service is very good: 40% from private, 26% for IMSS and ISSTE and 20% for SP

The public health care system in Mexico has responded with a number of policy efforts, including a program to encourage annual checkups, large scale programs to encourage active lifestyles, and a new tax in 2014 on sugary drinks and high-caloric foods.⁸ Despite these efforts, obesity rates have not receded in Mexico, and diabetes diagnosis rates have remained at 11% of the population since 2012 (INSP, 2018, 2012; Ángel Rivera Dommarco et al., 2018). Diabetes patients who do not have the disease under control face much higher risks of hospitalization and disability. Mexico has twice the rate of hospitalizations per diabetic rate than the OECD average, and diabetes was the second highest cause of death in the country in 2019 (OECD, 2019; Ojeda, 2019).

While public health care is free, widespread dissatisfaction with the quality and waiting times of the public sector has caused the rapid growth of private health care systems in Mexico. This private care is primarily focused at the primary level; the share of private medical offices went from 5% in 1990 to over 30% in 2020. (SSP, 2021; INSP, 2018). In 2018, 18.2% of diabetics reported getting treatment on private institutions. Patients affiliated to either the formal sector or INSABI programs can get their medications for free in the pharmacies of their clinics, but often choose to pay a small amount to reduce wait times by going to private pharmacies instead.⁹

3 The Mexico Diabetes Experiment

One of the private providers of disease care management is Clinicas de Azucar (“sugar clinics”). This chain of clinics was founded in the state of Monterrey by U.S. educated health care entrepreneur Javier Lozano. The first clinic was established in 2011, and the chain has grown to 17 clinics in 5 states.

The Sugar Clinics are a chain of specialized, diabetes clinics that provide affordable and comprehensive care. Each patient pays fixed-cost membership fees allowing him/her to have unlimited access to diagnostics, labs and consultations for one year. One of the main selling points of the clinics is that a patient can receive a full diabetes check-up with nutritionist assessments, and recommendations for diet, exercise and medication in under 90 minutes, avoiding several visits and long wait-times in the public sector. The approach used by CdA parallels a disease manage-

⁸ Aguilar et al. (2021), and Colchero et al. (2017).

⁹ Health Federal Law.

ment program generally applied internationally for chronic-obstructive pulmonary disease, certain types of cancer, and diabetes; a similar approach is used by Joslin Diabetes Center in Boston and Apollo Sugar Clinics in India.¹⁰ We therefore view our project as evaluating more generally the provision of privatized diabetes care. Although we cannot say with certainty whether the results from CdA extrapolate to other private providers, our findings on mechanisms in Section V suggest that the effects may be quite general.

Non-causal estimates of the impact of CdA are very promising. Estimates from CdA indicate that enrollees see their HbA1c levels fall by 2 points relative to baseline, and such an effect appears to be lasting. Based on these promising findings, we partnered with CdA to design an experimental intervention to assess the causal impact of their program, with funding from the Lilly Foundation. We preregistered in the AEA registry.¹¹

The past literature suggests two natural ways to set up such an experimental intervention. One would be to find and pay individuals to receive a free evaluation at CdA and to then potentially sign up for the service. This would have been extremely hard and expensive as it would have required us to test a large sample of individuals to assess whether they are diabetic, and then incentivize them to go to CdA clinics.

The other was to offer individuals who arrived at CdA for a free-screening a bonus for enrollment, which would target those on the margin of using the service. But this approach faced the problem that 60% of those who are offered the service are always takers. This limits the size of our potential first stage size; moreover, it would also imply that we would be giving a bonus to the 60% of patients that would have bought anyway. After running power calculations, we quickly realized that we could not afford to pay for this strategy and that we could only launch such an intervention if we managed to remove some always takers from the sample.

We therefore introduce a new approach of *deniers randomization*. Our experiment proceeds in several steps, as illustrated in Figure 1. When patients enter CdA clinics, we asked them if they would be willing to fill out a survey while waiting for the intake process to begin. After their free full check-up, individuals met with a physician who discussed their diagnosis and suggested a potential care package at CDA. We removed people who were not diagnosed with diabetes. After

¹⁰IQEHC (2007)

¹¹<https://www.socialscienceregistry.org/trials/3589>

that, individuals met with a sales force associate for potential enrollment under normal conditions (full price). If they decided to buy, they were removed from our experiment.

Our experiment began when potential enrollees indicated that they were not willing to buy. At that point, the sales force would ask if they were willing to be lotteried into an additional discount from our study, with a 50-50 chance of getting a 60% discount to CdA. If interested, the sales associate then (and, critically, not before) would consult the treatment/control status on their screen. If the individual showed up as being in the treatment group, the sales associate was then authorized to offer them a 60% discount. We used the consulted status to define our sample.¹²

We were particularly concerned that the sales force might not wait until after the enrollee declined to offer them the discount lottery, interfering with our randomization. We pursued three strategies to address this concern. First, we offered higher commissions to the sales force for full price than for discounted sales in order to properly align incentives. Second, we carefully instructed the agents on the importance of first ensuring a lack of interest in the full-price membership before offering the discount. Third, we had bi-weekly meetings with the entire sales force where we reviewed the process and reinforced which patients should be offered the discount. Moreover, we would present some hypothetical cases and ask the staff what they should do to ensure they understood the process.¹³

We recruited individuals over the period from June 2019 to February 2020, Figure 2 summarizes our recruitment. We approached 7,882 individuals who showed up at CdA offices for their free evaluation, who we randomly divided into a treatment group of 3,967 and a control group of 3,915. All of these individuals were asked to fill out a baseline survey while waiting to receive the complementary checkup. The survey contained basic demographic questions, whether each patient was previously diagnosed with diabetes and a set of questions comparing the sugar clinics to the public system. 94% of both the Treatment and Control arms completed at least some of the baseline survey.¹⁴ Moreover, we can see that among patients who filled out the survey, the sales force screened out 67% of the individuals according to the procedure described above and only

¹²We chose the 60% discount based on a pilot run with CdA which showed that such a discount yielded a 48% take up rate

¹³Our initial approach was to offer the discount via phone call 10 days after the initial visit, but take-up was under 20%, and rose only marginally when we waited only one day

¹⁴Overall, we have an 87% of surveys with complete demographic information which we use on our main specifications, and our results do not change when restricting the sample to full surveys

consulted treatment/control status for the remaining 33%.

The last row of Figure 2 shows, the final balance of our sample along a number of dimensions is excellent. We ended up with 1226 individuals in the treatment arm, and 1184 individuals in the control arm. They are very well balanced in terms of baseline HbA1c, weight and age. Importantly, there is a significant difference in the odds of using the services provided by CdA. Among the controls, 21% eventually enrolled in CdA, probably because of additional efforts made by CDA's marketing.¹⁵ Use was 28 points higher, at 49%, among the treatment group.

The advantage of our deniers randomization approach is an enormous gain in efficiency in the experiment. The cost for our actual experiment is an order of magnitude smaller than what it would have been if we would have randomly offered an incentive to every patient that walked in. The fact that 60% of patients are always takers would have made our first stage substantially weaker and we would have required a much larger sample, around 10 times as big in our setting, to have the same power. A larger sample also implies giving away more discounts as well as running more follow-ups. Since our follow-up was performed at patients' homes to prevent differential attrition, running extra surveys would be prohibitively expensive. We estimate that our budget was one-tenth what would have been required if we had included the always takers in our randomization.¹⁶

In order to capture the same local average treatment effect (LATE) as traditional approaches, the deniers randomization requires that at the consultation stage we do not screen out would-be compliers and that the process of being denied does not impact enrollment decisions. To minimize any bias along these lines, we continued to provide a financial incentive for staff to enroll those who turned down the initial offer (although, as noted above, the incentive was lower than for full pay enrollment), and we continually emphasized to staff the importance of ensuring that all patients receive this lottery opportunity. In our setting, it is unlikely that the timing of the offer affects enrollment decisions as patients ultimately get the offer immediately after saying they do not want to pay full-price. Of course, any randomization that occurs once individuals express

¹⁵Following typical CdA practice, never takers would be called several times during the next two weeks to encourage enrollment. These subsequent contacts would also offer additional small (10-20%) discounts over the full price.

¹⁶For this exercise we run power calculations for different average treatment effects with an 80% power and a first-stage power of 28% for our deniers randomization approach, compared to 9% for the discount to all those who enter CdA (assuming same set of compliers but 3 times the sample as 67% are screened out). Then we estimate expenses of follow-up and incentives.

interest in CdA does not capture the effect for the typical diabetic in Mexico, and we discuss issues of external validity below.

After an eight month enrollment period that ended on February 2020, our plan was to begin a follow-up starting in May 2020 but the COVID-19 pandemic interfered with the plans, as Mexico entered into lockdown from March 23rd to June 1 (Político, 2020). This raised two potential problems for our trial. The first is that individuals would stop interacting with CdA. In fact, in-person visits to CdA fell by 66% in April, but had returned to 95% of baseline by July. In the intervening time, CdA relied on telephone consultations with patients. These were likely at best partial substitutes for in person visits as the clinics were not able to utilize more advanced videoconferencing technology nor virtualize the required laboratory tests nor physical checkups, leading to a potential weakening of our effects.

The interference with data collection was more profound. The fact that the country was locked down meant a potentially catastrophic delay to our follow-up. Moreover, it was likely that some of our patients would no longer want to receive a surveyor at home to get their blood sugar tested and answer our follow-up survey. Ultimately, after incorporating a set of additional safety measures and personal protective equipment, we were able to follow up with 44% of the sample. Notably, as shown in Table 1, there was no differential attrition between treatment and control. In particular, we regress follow-up response on treatment status, and we find not correlation regardless of the richness of included controls.

The resulting sample is shown in Table 2; we show the means for control and treatment, as well as the difference, with standard errors in parentheses. The mean age of the control group is 52.4 years, and 32% are male; the lower male share may reflect the willingness of men to buy at full price, while wives may want to consult with spouses. 56% live in zipcodes that make above 15,000 USD a year, and 37% have at least high school. The mean level of HbA1c is 9.35, well above the control level of 7, and 76% of our sample is out of control. Mean BMI is 31, which is outside the recommended range of [18.5-25] and means that the average person who shows up to CDA is obese. Roughly 80% have access to public health systems. 67% of them had already been diagnosed with diabetes. And the self-reported level of trust in CdA is higher than that alternative providers.

Critically, we find no significant differences between treatment and controls , confirming the

validity of our randomization and the lack of attrition bias. There difference in HbA1c is an insignificant 0.15 points, which is only 1.6% of the mean and roughly one-eighth of our estimated treatment effect; the difference in the share out of control is an insignificant 0.03%, which is below 10% of the control mean and roughly one-seventh of our estimated treatment effect. The sample is also very well balanced on demographics and type of insurance coverage.

4 The Causal Impacts of CdA

4.1 Effect on Blood Sugar

We implement our evaluation of the experiment through a straightforward regression framework. We initially estimate OLS models of the effect of HbA1c of the form:

$$Y_{i,j,t} = \beta_0 + \beta_1 U_i + \Gamma_j + \psi_t + \chi_i + \epsilon_{i,j,t} \quad (1)$$

Where $Y_{i,j,t}$ is HbA1c values for individual i who enrolled in clinic j on month t , U_i is an indicator for using CdA services, Γ_j and ψ_t capture clinic and month of enrollment fixed effects and χ_i includes controls for baseline HbA1c, BMI, gender, age, schooling and income. These controls are missing for about 100 patients, lowering our regression sample size to 939; results are almost identical if we exclude the 5 variables and use the somewhat larger sample. Standard errors are robust. We then use the standard two stage least squares approach of instrumenting CdA usage by being in the treatment group to estimate the local average treatment effect of using CdA on our sample based on the same specification.

Our main results are shown in Table 3. Column 1 shows the OLS estimate of using the Cda services on blood sugar, which indicates that CdA lowers blood sugar by -0.98 points, off a base of 8.54 points. This is much lower than the 2-point estimate that CdA finds in following its enrollees. An important part of the difference is improvement among those who do not use CdA but may go elsewhere for care – in fact, we see that our control population improves 0.9 points relative to baseline. Another part of the difference could be through selection of those who stay in the program, and therefore continue to be measured by CdA’s internal metrics, and those who leave, who are also included in our evaluation.

Additionally, our evaluation does not incorporate the value of the initial evaluation done by CdA. Our estimate compares treatments and controls conditional on the initial evaluation. But if the initial evaluation itself has value in terms of helping potential enrollees to understand how to manage their diabetes, it could lead to some decline relative to their level of blood sugar at entry to the clinic.¹⁷ As a result, our experimental effect is a lower bound on the total impact of interacting with CdA.

The rest of the table shows the coefficients on the control variables. By far the most important control variable is baseline HbA1c, with each point in baseline HbA1c associated with a 0.5 percentage point level of HbA1c ex-post. The other significant relationship is with income, where being in the lowest income group is associated with HbA1c that is 0.57 points higher. Interestingly, we find little impact of BMI conditional on baseline blood sugar. The other coefficients are also insignificant.

Column 2 shows the corresponding IV estimate, where we instrument by the treatment indicator. We find an effect that is comparable, but about 10% bigger at -1.1 points. Another way to illustrate the effects of the intervention is to look at the share of individuals who have their blood sugar under control, defined as a level of HbA1c below 7. Columns 3 and 4 present these results. For this outcome, our IV estimate shows that 22% of individuals are brought under control by the intervention, which is more than two thirds of the baseline rate of control in our sample.

These are very large effects. For example, a set of recent meta-analysis shows that, on average psychological interventions reduce HbA1c by 0.32, physical activity interventions by 0.67-0.89, self-monitoring of blood-sugar by 0.39, dietary approaches between 0.12 and 0.47 and disease management programs similar to the one we are working with show reductions in HbA1c between 0.38 and 0.45 points, less than half of what we find.¹⁸ A widely cited study notes that a reduction of the magnitude we find in Table 3 is sufficient to reduce complications by 35% and reduce mortality by 4% (King et al., 2001; Arnold and Wang, 2014). Moreover, increasing the fraction of patients with HbA1c under control of control by 69% makes an enormous difference for life expectancy; each year a patient spends with diabetes out of control is estimated to reduce life expectancy by 100

¹⁷Note that this is not a particular limitation of our deniers randomization approach – any approach which conditioned on individuals arriving at CdA and being evaluated would suffer from this problem. To avoid this would require randomizing whether individuals attend CdA at all

¹⁸Ismail et al. (2004), Umpierre et al. (2011) Ajala et al. (2013) and Pimouguet et al. (2011b)

days (Heald et al., 2020).

4.2 Mechanisms

Our survey results allow us to explore a variety of mechanisms through which CdA may have had its effects. The results of this analysis are shown in Table 4, using the IV version of equation 1. All dependent variables come from the responses to the follow up survey; the number of observations varies.

We find that CdA enrollment leads to a very large increase in the odds of receiving medical care. Total physician visits increase by 2.6, which is 40% of the control mean. Column 2 shows the number of visits that involve specific check-ups on potential complications from diabetes, and we find that these almost double relative to baseline. The number of visits to diabetes specialists rises by almost 50%. An important mechanism is then that patients are getting more quantity of care.

We also find evidence for the key mechanism of drug compliance. In the follow up survey we ask individuals if they are likely to stop medication if they “feel good”. The right answer to this question is clearly no: diabetes cannot be cured, and ongoing medication remains very inexpensive compared to the underlying health risks. Yet 25% of enrollees in the control group answer yes, indicating inappropriate use of medication. We find that the estimated effect of CdA is a reduction of this response by 22%. Thus, by this measure of proper disease management, CdA causes an 88% improvement with respect to the mean.

Corresponding to this finding, we find a dramatic shift in how individuals intervene to manage their blood sugar. We see a significant rise in the use of cost effective (typically generic) blood sugar-reducing medication, with use rising by 25% from a baseline of 73%. Correspondingly, we see a 15% decline in the use of insulin, or 100% of baseline. This is an important finding for the efficiency of diabetes management, since insulin is more costly than sugar-reducing medication and is used at later stages of disease progression.

As noted earlier, CdA provides a full suite of interventions, including nutritional and exercise advice. Behaviors such as eating and exercise are notoriously difficult to influence (Jager, 2003). Yet we find suggestive evidence that, in the short term at least, CdA influenced these behaviors positively. Our follow up survey includes a dichotomous variable for whether individuals report dieting or engaging in exercise. We find that the odds of both exercise and diet rise by 14%, and

that there is a marginally significant increase in the odds of either diet or exercise by 26%, from a mean of 73%. We also find insignificant declines in the number of sodas and cigarettes consumed per week.

4.3 Heterogeneity

We explored a wide variety of dimensions along which we might find heterogeneous impacts. To model heterogeneity, we estimate the following model:

$$Y_{i,j,t} = \beta_0 + \beta_1 T_i + \beta_2 H_i + \beta_3 T_i * H_i + \Gamma_j + \chi_i + \epsilon_{i,j,t} \quad (2)$$

Where $Y_{i,j,t}$ is HbA1c values for individual i who enrolled in clinic j on month t , T_i is an indicator for being part of the treatment group, H_i is a dummy for whether the patient has a value higher than the median of the heterogeneity variable and Γ_j captures clinic fixed effects. The coefficient of interest for this analysis is β_3 . The results are shown in Table 5.

While our estimates are somewhat imprecise, we find no significant heterogeneity across age, sex, BMI or schooling. We do find that there is significant heterogeneity by baseline level of HbA1c. Sicker individuals at baseline improve more than their healthier counterparts. To further understand how our effects are distributed we apply [Athey and Wager \(2019\)](#)'s method for conditional average treatment effects. Briefly, the method trains a causal forest which enables the estimation of the average treatment effect for each patient in the experiment. To start, a forest is trained using random subsamples of the data; next the algorithm gathers a weighted list of the sample's neighbors based on what leaf nodes of the tree it falls in; finally, the treatment effect is calculated using the outcomes and treatment status of the neighbor examples.

We use these estimates to assess the impact of our deniers randomization approach versus an approach that would include always takers in randomization, we show the CATE for both our enrollees and the set of always takers we screened out in the first step of the experiment's protocol. Figure 3 compares the CATE of both distributions. Here we can see that the effect of CDA is slightly bigger on average than that of our complier sample. This could be explained if people with higher returns are more likely to enroll.

5 Fiscal Externalities on the Public Sector

In many public systems such as Mexico's, privatized care is provided at lower levels of care, but the costs of higher levels of care are primarily borne by the public sector. In Mexico, there is relatively little private hospital care, even among those who use private sources for their primary care. While 70% of hospitals are private, only 24% of beds are represented by them. From our sample, 74% of individuals who utilized a hospital report a public option as their main health provider. As a result, improved primary care through private diabetes clinics may impart a significant fiscal externality on the public sector.

Indeed, the hospital costs of diabetes to the Mexican public insurance system are enormous. Total costs amount to 2.25% of GDP, with 1.1% being direct medical costs and 87% of this total is due to complications. These costs primarily arise from a series of complications associated with diabetes such as diabetic retinopathy, diabetic foot and diabetes kidney disease.¹⁹ Bringing blood sugar levels under control significantly reduces the risk of such complications – leading to reduced hospital costs (Barraza-Lloréns et al., 2015). The fact that Mexico has twice the OECD average diabetic hospitalization rate highlights that there is much to gain from improving early-stage care.

We investigate this in two ways. First, we directly estimate the effect of CdA on self-reported diabetic complications. This is challenging since we only have a short follow up time for our CdA enrollees, so that we will meaningfully understate the long-term impacts on complications. Second, we use a simulation model based on our estimated reduction in blood sugar, combined with the best estimates of the marginal impacts of reduced blood sugar on future complications.

Column 1 of Table 6 shows our estimated treatment effects for complications, which are defined as the sum of the early symptoms a person might experience. Despite the short follow up, we find a significant reduction in complications, with enrollment associated with a decline of complications of -0.25 off a base of 1.4.

¹⁹*Diabetic retinopathy*: is a diabetes complication that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). At first, diabetic retinopathy may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. *Diabetic foot*: Diabetes can damage your nerves or blood vessels. Nerve damage from diabetes can cause you to lose feeling in your feet. You may not feel a cut, a blister or a sore. Foot injuries such as these can cause ulcers and infections. Serious cases may even lead to amputation. *Kidney disease*: Diabetes can damage the blood vessels in your kidneys. When the blood vessels are damaged, they don't work as well. When your kidneys are damaged, they can't filter blood like they should, which can cause wastes to build up in your body.

To put this result in context, we compute the estimated decline in complications that we would expect over time based on our blood sugar reductions. According to the widely cited UKPDS study, a point reduction in HbA1c could lower the likelihood of complications by 35%- significantly higher than the 18% we find experimentally, which is unsurprising given our short term follow up.

We next turn to estimating the fiscal externality, in six steps, recognizing the important heterogeneity in impacts by baseline blood sugar levels. First, we classify our sample into HbA1c baseline value bins, using the smaller nearest integer. Second, for those in the control group, in each bin we averaged their HbA1c observed at follow up ($HbA1C_{C_j}^{followup}$). Third, to go from HbA1c levels to health complications, we use the complications incidence tables by level of HbA1c from the widely cited UKPDS 35 study (King et al., 2001).²⁰ This gives us the estimated complications for the control group by bin. Fourth, we apply an analogous method for the treatment group. We start from their baseline level and add in the conditional local average treatment effect (CLATE) of the respective bin, where the estimate is done as above but separately for each bin. That is for each bin j we calculate the number $HbA1C_{T_j}^{followup} = HbA1C_{T_j}^{baseline} + CLATE_j$, and map these to health complications. Fifth, we define averted hospitalizations as the difference expected hospitalizations between treatment and control group for each bin. Finally, to estimate the savings to the system from reduced hospitalizations, we multiply what each complication costs by the averted hospitalizations using the cost data from Barraza-Lloréns et al. (2015) for 2013 in Mexico updated for inflation.

Figure 4 showcases our results. The vertical bars represent the savings in pesos (left Y-axis) estimated per patient year at each level of baseline HbA1c. These generally rise with HbA1c levels both because (a) the rate of complications is higher for those with higher blood sugar and (b) our CLATE estimates show larger effects of our intervention for those with higher blood sugar at baseline. The moving blue line shows the distribution of HbA1c at baseline in our sample (measured in the left Y-axis), and the horizontal line shows the annual subscription price of CdA. Our results show that at high levels of blood sugar, the program essentially pays for itself in reduced hospital spending; overall, we estimate that reduced hospital expenditures amount to 55% of the cost of

²⁰For each group, we interpolate linearly between the 2 HbA1c integer numbers that the incidence tables in the paper report. Since dynamics of the effect of higher blood sugar for each complication vary, we estimate incidence for each main complication separately. We focus on neuropathy, ulcers, amputations, ophthalmic complications, diabetic coma, nephropathy, stroke, and heart attack.

CdA.

Of course, these calculations are not precise. On the one hand, we assume that the marginal reductions in blood sugar from our intervention have the same impact as the average reduction in blood sugar used by UKPDS 35. On the other hand, we only consider the direct fiscal externality from hospitalizations averted and do not consider the savings from care substitution (with the CdA visits displacing public visits). To address this, we directly measure care substitution in the next two columns of Table 6. The second column measures visits to a public insurance provider. This falls by 0.11 visits, or about one fifth of the control group mean at baseline, but the estimate is insignificant. One problem with this measure, however, is that COVID-19 may have had the impact of reducing all medical care use, for both treatments and controls, mitigating any estimated displacement effect. The next column uses a measure which may be more reliable, whether the respondent considers the public health system to be their main health care provider. While this variable has essentially the same mean, our estimated effect is nearly twice as large, and amounts to 40% of baseline mean.

At baseline, our control group has 5 visits on average to their public provider in the year before joining CdA. The direct cost to IMSS of each visit is 800 pesos. In addition, IMSS data shows that the total cost of maintaining care for an under control diabetic is \$9000 pesos per year. So a 20% reduction in visits would save \$800-\$1800 pesos per year; if we use the larger estimate from the third column of Table 6, we would have savings of \$1600-\$3600 pesos per year.

Recall that for our sample the cost of CdA treatment for one year was \$7000 pesos. Using our estimate of offsetting hospital spending on complications, as well as our lowest estimate of offsetting primary care expenditures, roughly 65% of the costs of CdA are offset by reduced public sector costs; at the upper bound, the offset is 105%. In either case, the net cost of this incremental care through CdA is much less than the gross costs.

Even using the gross costs, however, our estimates suggest that this treatment is highly cost effective. In Table 3, we show that patients enrolled in CdA are 22% more likely to be in control than those who do not enroll. The medical literature estimates that every year that a diabetic patient spends out of control reduces life expectancy by 100 days.²¹ Typical estimates of the value of a life-year in international contexts is in the \$50,000-\$100,000 range, which would suggest that

²¹Heald et al. (2020)

this intervention is worth \$3000-\$6000 per person, many multiples of gross or net program costs.²²

While estimating the value of life in this particular population is beyond our scope, it is worth noting that even this estimate excludes the valuation of the large reduction in morbidity – which does not only save the public sector costs but improves quality of life

6 Why Does the Private Sector Improve Outcomes?

The striking finding that enrolling in CdA dramatically improves health outcomes for diabetics that have access to free public care raises the key question of *why* the private sector is doing a better job than the public sector addressing the medical needs of diabetics. One potential explanation is that our finding is driven by heterogeneity in the type of public insurance. While there is technically universal public coverage in Mexico, the care delivered by the formal sector social insurance programs is typically perceived to be much higher quality than that delivered by the residual public welfare program, Seguro Popular. As a result, if our findings are driven by those individuals in our sample who are not formally employed and have to rely on Seguro Popular, this may reflect the lower quality of care in that public program. However, we find no evidence that the impact of CdA is driven by informal workers – if anything, the opposite appears to be true.²³

If even the higher quality public programs do not perform as well as private care, the difference must be explained by either quality or quantity differences between the two platforms. On the one hand, it could be the case that CDA is providing a higher quality of service per interaction. On the other hand, perhaps CdA is doing more to attract diabetics to interact with care, improving outcomes through quantity rather than quality. To separate these hypotheses, we supplement our analysis with an estimate of the marginal return to public care.

In particular, we incorporate data from the IMSS program, the largest formal sector health care system in Mexico, between 2010 and 2015. We worked with IMSS to collect administrative data for every primary care visit and the place of residence for all enrollees; this is a novel data set which has not been previously exploited for economics research. The data combines several

²²Lee et al. (2009) argues that the value per year of quality life is \$129,00 but \$50,000-\$100,00 has been de facto international standard. For the calculation we multiply the effect on likelihood of control, times 100/365 days, times \$50,000-\$100,000.

²³A regression of HbA1c on treatment interacted with having informal insurance shows a positive but insignificant interaction – suggesting that our results are not driven by larger impacts among those informally insured, see last column Table 5.

large administrative datasets. First, annual testing data. All IMSS enrollees are supposed to have a check-up that includes blood sugar once per year as part of the PrevenIMSS program and we have administrative data for the 73 million checkups recorded in that period.²⁴ Second, we have administrative data from every primary care visit that includes ICD-10 codification. On average there are around 80 million visits per year, so we have over 400 million observations total. Third, we have exact location data for 47 million families' homes. Fourth, we have an infrastructure dataset that includes geocoded locations for the nearly 1,500 primary care clinics providing care through IMSS. In order to estimate the marginal return to care, we create a sample of all patients who have been treated for diabetes at IMSS and who had at least one PrevenIMSS checkup, leaving us with a sizeable sample of 440,000 diabetics. Moreover, 160 thousand have a second Prevenimss appointment one year later, which allows us to track their blood sugar dynamics.

We use these data to estimate the marginal returns to additional IMSS care versus care from CdA. To assess the marginal returns to IMSS, we use variation in the distance of individuals from their IMSS clinic. Individuals in IMSS are assigned to a local clinic based on fixed geographic designations, and as a result, the distance from homes to an IMSS clinics varies substantially. Figure 5 shows the distribution of distances from individual homes to IMSS clinics, which varies substantially.

We restrict our analysis sample further to patients with two measures of blood sugar from PrevenIMSS, one year apart. We can use these measurements to assess whether more care during the intervening year induces improved outcomes – instrumenting the amount of care received with distance from an IMSS clinic.

In particular, we will estimate models of the following form:

$$Y_{i,j,t} = \beta_0 + \beta_1 N_{t,i} + \beta_2 Y_{t-1,i} + \Gamma_j + \psi_t + \chi_i + \epsilon_{t,i,j} \quad (3)$$

Where the dependent variable $Y_{i,j,t}$ is the level of blood sugar for individual i who got his checkups at clinic j at time t , $N_{t,i}$ is the number of visits to IMSS clinics in the 12 months after the first blood sugar measurements, Γ_j captures clinic fixed effects, ψ_t captures month fixed effects and χ_i are demographic control variables (gender, age and age-squared). We instrument the number

²⁴IMSS (2013)

of visits with the distance from residence to the assigned IMSS clinic.

This quasi-experimental approach faces two key identification concerns. The first is that distance is correlated with underlying health. We address this by controlling for baseline blood sugar at time $t-1$, so that we are assessing the impact of visits on the improvement in blood sugar. Of course, this does not solve the underlying identification problem if those who live near IMSS clinics are on differential underlying health trajectories than are those who live far away. But the inclusion of clinic fixed effects control for any neighborhood factors that might drive such trends.

The second concern is that the measurement itself may be correlated with distance – e.g. those who live farther away may be differentially likely to get their blood sugar measured. This is a particular concern given that only 160,000 out of 440,000 patients have a second yearly check-up. We can address this directly by assessing whether the odds of blood sugar measurement is itself correlated with distance.

The results of our analysis are shown in Table 7. The first column shows the first stage estimate of the impact of distance on the number of IMSS visits. The coefficient is highly significant, indicating that each 30 kilometers of distance results in .1 fewer visits. The second column tests for selection in having a blood measurement. In fact, we see no evidence of a correlation between likelihood of second check-up and distance.

We then turn to causal estimates of the impact of visits on blood sugar. Since PREVENIMSS captures capillary blood sugar measurements rather than HbA1c, we utilize that metric instead for our analysis. To compare to our earlier findings, our experimental results are equivalent to a reduction from 226 to 197.²⁵

We begin by estimating equation 3 for our CdA intervention. That is, we regress blood sugar levels on number of CdA visits, controlling for baseline blood sugar. We instrument number of visits with our treatment indicator, so that we are essentially measuring the total treatment effect as a function of number of visits. Remember that our treatment effect excludes the impact of the initial evaluation (which occurs for both treatments and controls), so that in this specification we are assuming linear impacts of each additional CdA visit. The third column of Table 7 shows that each CdA visit reduces blood sugar by 8 points

²⁵We utilize a conversion from Nathan et al. (2008). Notably similar to what we find experimentally from enrolling through our IV, an effect of 29 capillary points

The fourth column estimates equation 3, instrumenting by distance to an IMSS clinic, to estimate the estimated return on each marginal visit at IMSS. We find that each additional visit provides a benefit of 5 points. While significant, this is less than two-thirds as large as the estimate for CdA (although the differences between CdA and IMSS are not statistically significant). This suggests that part of the reason for a larger effect for CdA is more effectiveness per visit; moreover, as noted earlier, we potentially understate the impact of CdA because this treatment-control comparison excludes any impacts of the initial evaluation.

But this result does not account for potential selection on treatment effectiveness. In fact, those who sign up for CdA have considerably higher blood sugar than the typical person in IMSS, while the average baseline blood sugar in CdA is 225, at IMSS it is 135. And we showed earlier that the effect of CdA is larger for those with higher blood sugar – the same may be true for IMSS. To assess this, we re-estimate the regression for IMSS from column 4, but reweighting the sample by baseline blood sugar to make them more comparable. The final column of Table 7 shows that doing so dramatically increases the estimated IMSS treatment effect, which more than doubles. Indeed, this estimate is higher than the comparable CdA estimate, although not significantly so. Thus, these results do not indicate that CdA's impacts arise through a better "technology," at least in terms of the returns per visit.

The other reason for CdA's effectiveness would be that treatment individuals use more total care and are more willing to attend appointments at CdA. In fact, a host of evidence suggests that this is the case. Most importantly, Table 4 showed directly that the treatment group has more visits to doctors. Table 2 also finds a much higher level of trust in CdA than their alternative care provider, suggesting a higher willingness to engage with the provider. The changes in trust across time strengthen this. In Table 8 we explore whether the CdA trust advantage grows as a result of treatment. The first column regresses the difference in the self-reported trust²⁶ between CdA versus the alternative at follow up against our instrumented use CdA indicator, controlling for the baseline difference. The second column carries out the same exercise for a different variable, which measures whether enrollees trust *the diagnoses* that comes from CdA as opposed to their current health provider. Both variables have a mean difference above 2 points on a ten point scale. And

²⁶The questions are: *Do you think that if you follow the recommendations of CdA, you will improve your health substantially?, Do you think that if you follow the recommendations of IMSS, you will improve your health substantially? and Do you think that if you follow the recommendations of Seguro Popular, you will improve your health substantially?.*

IV regressions of this gap in beliefs on being a CdA user shows that the gap increases significantly with use of CdA. These results highlight that patients are more engaged with the service once they use it – which may lead them to get care more often.

Moreover, the experience at CdA appears to be higher quality along one critical dimension: waiting time. Our follow up survey asked treatments and controls about their waiting time for care. Column 3 of Table 8 shows our IV estimates for waiting time, and the impacts are striking: a reduction of 30 minutes in waiting time, or more than half of the baseline mean. Note also that this is an estimate per visit. While CDA offers a one-stop-shop model of care, the public sector usually requires the patient to visit several times because of slow lab-processing times and low availability of testing.

To further explore whether making care more accessible is the key mechanism, we focus on the subsample of our treatment and control groups that is enrolled in IMSS, and we consider the heterogeneity of our treatment effect by the level of IMSS clinic “saturation”, a direct measure of how hard it is to access care at IMSS. If indeed the key mechanism is through more access to care rather than better care, one would expect our effect to be bigger among the IMSS users who have to utilize a more saturated clinic.²⁷

Using data on visits from the period 2006-2016 for 31 clinics in the region, we match each patient to the closest IMSS clinic to their home and exploit administrative data to define clinic saturation. We begin by dividing the number of patients seen at the clinic by the number of medical office in that clinic. We take as a benchmark the 15 minutes per visit recommended by IMSS guidelines. We then label a clinic as “saturated” if they have on average at least 85% (3.4 visits) of the maximum 4 visits per hour they can handle at maximum capacity per year. We then rerun our outcomes regressions, interacting our treatment dummy with a dummy for the closest clinic being saturated; we redo the exercise for non-IMSS users as a placebo, matching non-IMSS users to the nearest IMSS clinic.

In the first column of Table 9, we show that our treatment effect is larger for IMSS users when the clinics are more saturated, consistent with the notion that it is those who face the largest barri-

²⁷This comparison assumes that the more saturated clinics don’t themselves deliver very different quality of care than less saturated clinics. If the care delivered at more saturated clinics is lower than at less saturated clinics, then part of the response we see here may be through differences in quality and not quantity. Of course, if saturation arises because there is more use of the highest quality clinics, the bias would go in the opposite direction.

ers to IMSS care who benefit most from CdA. Moreover, in the second column we show that such a relationship does not exist for the patients who are not enrolled at IMSS; in fact the point estimate goes in the opposite direction. We see this evidence as supporting the hypothesis that the improvements due to CdA arise through more care, rather than higher quality care – so that improving access to care would go a long way in terms of better health control for chronic-degenerative diseases.

7 Conclusion

Ongoing debates over private versus public delivery of health care are central throughout the world. Yet these arguments often take place on grounds of political philosophy and not empirical evidence. This is unsurprising, as it is challenging to design studies that compare private versus public options for enrollees in an empirically compelling framework.

This paper introduced such a framework, relying on a novel deniers randomization framework to run a trial of the private provision of diabetes care to a publicly insured population in Mexico. Our findings are striking: supplementary private care causes a highly significant and large reduction in the blood sugar levels of diabetics, increasing blood sugar control by more than two-thirds. We estimate that this occurred through improved use of medication, more frequent medical treatment, and more diet and exercise. This sizeable reduction in blood sugar was associated even within the first year with reduced diabetes complications. These large health effects suggest that this supplemental private service was highly cost effective. We estimate that two-thirds or more of the cost of the private program are offset by reduced public primary and (especially) hospital care, and that the estimated health benefits are many multiples of either gross or net costs

Interestingly, our results also suggest that the strong performance of this private sector alternative was not because of dramatic improvement in care modality, but rather through stronger attachment of patients to the private alternative due to shorter wait times and other advantages over public clinics. This suggests that much of the gains from privatization in this context could actually be captured by the public sector itself by improving access to care for its enrollees. An open and important question for future work is whether the public sector could best improve care by contracting out to the private sector or by expanding its own resources.

Our approach does have some limitations. We argue that our deniers randomization approach is an innovative means of cost-effectively evaluating an alternative like CdA, and show that based on our estimated heterogeneity in treatment effects, the estimates are likely to apply to always takers; but our heterogeneity estimates are noisy and more work is needed to confirm this approach. We also examine a particular program, CdA, and outcomes may not extend to other alternatives that are designed differently. Moreover, our conclusion that the gains from privatization are simply in increased care, and not in substantial changes to the technology of care, may reflect the particular case of diabetes, where there is a standard and cost-effective course of treatment. For other diseases with less standardized and/or more expensive treatment modalities, private delivery may or may not offer gains in the quality as well as the quantity of care.

Despite these caveats, however, our study provides a framework for estimating the effects of privatization on medical care. We focus here on diabetes, one of the world's deadliest chronic conditions, in Mexico, one of the countries where this problem is largest. The lessons from diabetes in Mexico could be usefully tested and applied to other diseases and other nations around the world.

Tables

Table 1: Attrition

	Answered follow up		
	(1)	(2)	(3)
Treatment	0.025 (0.020)	0.026 (0.020)	0.014 (0.021)
Branch FE	No	Yes	Yes
Enrollment Month Fe	No	Yes	Yes
Basic Controls	No	No	Yes
Observations	2,410	2,410	2,042
R-squared	0.001	0.011	0.109
Mean dep. var.	0.43	0.43	0.43

Notes: This table presents the results from running a regression on a dummy of answering follow-up on the treatment group dummy. The first column reports the regression without any controls, the second column controls for branch fixed effects and enrollment month fixed effects and the third column also includes Basic Controls: age, gender, HbA1c, BMI, Schooling and Income. Robust standard errors in parentheses. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.

Table 2: Balance Table for Those Measured at Follow Up

Variable	Control		Treatment		Difference C-T
	N	Mean/SE	N	Mean/SE	
<i>Panel A: Demographics</i>					
Age	509	52.39 (0.50)	558	53.06 (0.52)	-0.67 (0.73)
Male	509	0.32 (0.02)	558	0.35 (0.02)	-0.03 (0.03)
% High income	509	0.56 (0.02)	558	0.56 (0.02)	-0.01 (0.03)
% High School or more	457	0.37 (0.02)	485	0.39 (0.02)	-0.02 (0.03)
<i>Panel B: Health and Health services</i>					
HbA1c	508	9.35 (0.11)	556	9.51 (0.11)	-0.15 (0.16)
BMI	509	31.07 (0.27)	557	30.83 (0.25)	0.24 (0.37)
Has IMSS, ISSSTE or Seguro Popular	509	0.78 (0.02)	558	0.79 (0.02)	-0.01 (0.03)
Percentage that use IMSS, ISSSTE or Seguro Popular	509	0.74 (0.02)	558	0.74 (0.02)	0.00 (0.03)
HbA1c out of control (HbA1c>10)	508	0.38 (0.02)	556	0.41 (0.02)	-0.03 (0.03)
<i>Panel C: Beliefs</i>					
Trust to improve following CDA recomendations (0-10)	432	9.43 (0.07)	467	9.54 (0.06)	-0.12 (0.09)
Trust to improve following current health provider recomendations (0-10)	414	7.89 (0.13)	460	7.93 (0.13)	-0.03 (0.18)
Trust in CDA diagnosis (0-10)	444	9.33 (0.07)	469	9.37 (0.07)	-0.04 (0.09)
Trust in current health provider diagnosis (0-10)	411	7.93 (0.13)	450	7.88 (0.13)	0.05 (0.18)

Notes: This table presents the balance among the patients who did answer our follow-up. (1) % High income: Is an indicator variable equal to 1 if the person lived in zip codes that the AMAI classifies as above middle income. This variable is an administrative variable and is based on the place of residency of each potential client at CdA. (2) Has IMSS, ISSSTE or Seguro Popular: Is an indicator variable equal to 1 if the person declared to be affiliated to a public service to the medical staff at CdA. (3) Percentage that use IMSS, ISSSTE or Seguro Popular: Is an indicator variable equal to 1 if the person declared to go for medical attention to the public services in our baseline survey. (4) Trust to improve following CDA recommendations (0-10): Is variable that measures the trust in improving with CdA. (5) Trust to improve following current health provider recommendations (0-10): Is a variable that measures the trust in improving with their current health provider. Robust standard errors in parentheses. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.

Table 3: Effect on HbA1c

	HbA1c OLS	HbA1C	Under Control- OLS I(HbA1C<7)	Under Control I(HbA1C<7)
	(1)	(2)	(3)	(4)
Use Cda	-0.98*** (0.13)	-1.12*** (0.41)	0.15*** (0.03)	0.22** (0.09)
HbA1c BI	0.50*** (0.03)	0.50*** (0.03)		
I(HbA1c<7) BI			0.51*** (0.04)	0.52*** (0.04)
BMI	-0.02 (0.01)	-0.02 (0.01)	0.00 (0.00)	0.00 (0.00)
Age	-0.00 (0.01)	-0.00 (0.01)	0.00 (0.00)	-0.00 (0.00)
Gender	-0.17 (0.14)	-0.17 (0.14)	0.04 (0.03)	0.03 (0.03)
Elementary School	0.28 (0.42)	0.30 (0.43)	0.06 (0.09)	0.05 (0.09)
Secondary School	0.43 (0.42)	0.44 (0.43)	0.04 (0.09)	0.03 (0.09)
High School	0.05 (0.44)	0.06 (0.45)	0.05 (0.09)	0.04 (0.09)
Tecnica o Normal	0.22 (0.44)	0.23 (0.44)	0.10 (0.09)	0.09 (0.09)
University	-0.08 (0.47)	-0.06 (0.48)	0.14 (0.10)	0.12 (0.10)
Income C+	0.26 (0.31)	0.25 (0.31)	-0.04 (0.12)	-0.04 (0.12)
Income C	0.24 (0.29)	0.23 (0.29)	-0.06 (0.11)	-0.05 (0.12)
Income D+	0.57* (0.31)	0.56* (0.31)	-0.15 (0.12)	-0.14 (0.12)
Income D or Lower	0.41 (0.32)	0.40 (0.32)	-0.09 (0.12)	-0.08 (0.12)
Observations	939	939	939	939
R-squared	0.36	0.35	0.26	0.22
F		93.26		93.33
First coeff		0.301		0.300
Mean dep. var	8.538	8.538	0.322	0.322

Notes: This table shows the results of estimating equation 1. The first column captures the OLS regression on the effect of using CdA on HbA1c, the second column captures the local average treatment effect (LATE) on HbA1c from our randomization, the third column captures the OLS regression on a dummy that captures if an individual has controlled his diabetes (HbA1c<7) and the fourth column captures the LATE from our experiment in terms of controlled diabetes.. In all regressions we are controlling for branch and month fixed effects as well as basic demographics control (age, sex, BMI, baseline HbA1c or controlled diabetes at baseline, schooling and income). Our schooling controls are self-reported from our baseline survey and the income controls are from administrative data from CdA; this administrative data use the locations of houses and the Asociación Mexicana de Agencias de Investigación y Opinión Pública A.C. classification: A/B upper class, C+ upper middle class, C middle class, D+ medium-low class and D lower class. Robust standard errors in parentheses. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.

Table 4: Mechanism

	Visits to Doctor	# Special Check ups	# Specialists	Waiting time	Stop med if feels good	Takes Pills	Takes Insulin	I(Exercise)	I(Diet)	Diet+Exercise	# Cigaretts	# Sodas
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
Use Cda (instrumented)	2.59** (1.06)	1.32*** (0.38)	0.64** (0.27)	-30.33*** (9.02)	-0.22** (0.09)	0.25*** (0.09)	-0.15** (0.06)	0.14 (0.10)	0.14 (0.10)	0.26* (0.15)	-0.72 (0.80)	-0.06 (0.14)
Branch FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Months since enrollment FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Controls Basic	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Observations	878	817	940	739	815	913	913	940	940	940	774	857
R-squared	0.04	0.03	0.10	-0.05	0.05	0.09	0.14	0.05	0.06	0.07	0.45	0.15
F	98.82	83.46	96.13	82.49	91.35	99.83	99.84	96.10	97.31	97.12	78.83	104.7
First coeff	0.321	0.307	0.306	0.325	0.323	0.315	0.316	0.306	0.308	0.308	0.307	0.332
Mean dep. var	6.502	1.408	1.383	43.46	0.249	0.727	0.134	0.289	0.436	0.725	0.911	0.841

Notes: This table presents the results for regressions of the form of equation 1 on different self-reported behaviors. For all of these specifications we are reporting the local average treatment effect (LATE) that we causally estimated from our experiment using instrumental variables. In all regressions we are controlling for branch and month fixed effects as well as basic demographics control (age, sex, BMI, baseline HbA1c, schooling and income). (1) *Visits to Doctor*: Is a variable that captures how many visits to the doctor related with diabetes the person had the last year. (2) *# Special Check Ups*: Is a variable that sum the check ups that the person received during the last year related with diabetes, i.e eyes, kidney, foot and blood check ups. (3) *# Specialists*: Is a variable that captures the number of specialist, related with diabetes, who attended the person in a regular visit to their health provider. (4) *Waiting Time*: Is a variable that captures the waiting time whenever the persons attend to his health provider to have an appointment related with diabetes, we winzorized at 5% the upper tail to omit implausible waiting times. (5) *Stop Medication if feels good*: Is an indicator variable equal to 1 if the person declared that he suspended his medication whenever he start to feeling good. (6) *Takes Pills and Takes Insulin*: Both are indicator variables equal to 1 if the person declared that he took pills and/or insulin respectively as a part of his treatment, also we control for their baseline measure. (7) *I(Diet) and I(Exercise)*: Both are indicator variables equal to 1 if the person declared that he did exercise and was involved in a diet as an effort to take care of his health. (8) *Diet+Exercise*: is a variable that sums the variables *I(Diet)* and *I(Exercise)*. (9) *# Cigaretts and #Sodas*: are variables that captures the number of cigarettes and sodas consumed in a regular day by the person, also we control for their baseline measure. Robust standard errors in parentheses. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.

Table 5: Heterogeneity Effect*Dep Var HbA1c follow up*

	Age	Male	Income	Schooling	HbA1c	BMI	Informal
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
Treatment	-0.5125** (0.2130)	-0.4042** (0.1729)	-0.2938* (0.1566)	-0.3679* (0.1951)	-0.1687 (0.1251)	-0.2125 (0.2084)	-0.4062** (0.1637)
Regressor	-0.6622*** (0.2077)	-0.0091 (0.2278)	-0.5085* (0.2931)	-0.5705** (0.2246)	2.2659*** (0.1914)	-0.3409 (0.2118)	0.0863 (0.2366)
Treatment X regressor	0.4571 (0.2785)	0.2782 (0.3048)	-0.1074 (0.3657)	0.2097 (0.3065)	-0.4253* (0.2553)	-0.2063 (0.2824)	0.3137 (0.3209)
Branch FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Controls	No	No	No	No	No	No	No
R2	1,067	1,067	1,067	942	1,064	1,066	1,067
Num. Obs	0.0281	0.0191	0.0249	0.0272	0.2149	0.0274	0.0209

Notes: This table presents the heterogeneity results from the effect of getting CDA treatment on health, estimated from including in equation 2 an interaction with the regressor listed at the top of each column. For each of these, we report the treatment coefficient, the baseline effect on the explored dimension and the interaction between the 2. In all regressions we are controlling for branch fixed effects. For the variables age, HbA1c and BMI we split by the median. For the variables income and schooling we split for those considered middle or upper class and those with high school or higher education respectively. Informal: is an indicator variable equal to 1 if the person declared to be affiliated to the Seguro Popular or to not have social insurance to the medical staff at CdA. Robust standard errors in parentheses. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.

Table 6: Averted complications and Health Provider Substitution

	Total Diabetes Complications	Use of Public Service	Public Service as Principal Provider
	(1)	(2)	(3)
Use Cda	-0.25* (0.13)	-0.11 (0.10)	-0.25** (0.10)
Branch FE	Yes	Yes	Yes
Enrollment Month Fe	Yes	Yes	Yes
Basic Controls	Yes	Yes	Yes
Observations	939	940	909
R-squared	0.05	0.09	0.14
F	93.31	96.06	95.34
First coeff	0.301	0.306	0.310
Mean dep. var	1.383	0.611	0.640

Notes: This table presents the results from the effect of getting CDA treatment on complications, the effect of using CDA on utilizing the public sector and the effect of CDA on saying that the public sector is your main provider. We are controlling for branch and month fixed effects as well as basic demographics control (age, sex, BMI, baseline HbA1c, schooling and income). (1) *Total diabetes complications*: Is a variable that sum the short run complications related to diabetes experienced by the person, i.e eyes, feet and hand tingling, we also control by the total complications at baseline. (2) *Use of Public Service*: Is an indicator variable equal to one if the person declared to attended to IMSS, Seguro Popular or ISSSTE in the previous year for any medical reason, we also control for the baseline value of this variable. (3) *Public Service as Main Provider*: Is an indicator variable equal to one if the person declared a public service (IMSS, Seguro Popular, ISSSTE) as their principal health provider, we control for their health affiliation at baseline. Robust standard errors in parentheses. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.

Table 7: Comparison IMSS vs Cda Effect

	IMSS		CdA	IMSS	
	Number of medical visits	I(12 months follow up)	Capillary Glucose	Capillary Glucose	Capillary Glucose
	(1)	(2)	(3)	(4)	(5)
Distance (km)	-0.0030*** (0.0005)	0.0001 (0.0000)			
Number of medical visits			-8.3936** (4.0728)	-5.0737* (2.6946)	-12.6946** (6.4316)
Observations	160,035	439,287	1,067	160,035	137,308
R-squared	0.1149	0.0546	0.1741	-0.0562	-0.2812
F			60.31	35.29	12.96
First coeff			1.284	-0.00304	-0.00198
Instrument			Discount	Distance	Distance (W)

Notes: All columns except (3) estimated in IMSS data. First column shows regression of number of visits at IMSS on distance from the clinic. Second column shows regression of dummy for having a follow up blood sugar measurement on distance. Third column shows IV regression in CdA data where we regress capillary glucose on number of visits, instrumented by treatment indicator. Fourth column shows an IV regression of capillary glucose on number of IMSS visits, instrumented by distance. Fifth column repeats this exercise but reweighting the sample so that the baseline distribution for capillary blood sugar matches that of CDA. All specifications have branch and month fixed effects and basic controls (age, age squared, initial capilarity glucose and gender). All specifications have branch and month fixed effects and basic controls (age, age squared, initial capilarity glucose and gender). Robust standard errors in parentheses. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.

Table 8: Effect on Trust and Waiting Time

	Dif Trust in Improving (1)	Dif Trust in Diagnosis (2)	Waiting time (2)
Use Cda	1.9223*** (0.5991)	1.4831** (0.5973)	-30.33*** (9.02)
Branch FE	Yes	Yes	Yes
Enrollment Month Fe	Yes	Yes	Yes
Basic Controls	Yes	Yes	Yes
Observations	682	676	739
R-squared	0.0181	0.0177	-0.05
Mean dep. var	2.107	2.292	43.46
F	82.97	92.88	82.49
First coeff	0.330	0.348	0.325

Notes: This table presents the results from the effect of getting CDA treatment on trust and waiting time. The first column captures the local average treatment effect (LATE) on the difference in the self-reported trust that the patient will improve their health through CdA, as opposed to through their health provider at baseline (the difference in the rows shown in Table 2), we also control by the baseline measure of the variable which is define as the difference from the baseline survey on the same questions. The second column carries out the same exercise for patients' trust in diagnoses that come from CdA as opposed to their health provider at baseline, we also control by the baseline measure of the variable which is define as the difference from the baseline survey on the same questions. The third column reports our results on waiting time. On our follow-up survey we asked how long do patients usually wait at the doctor they usually go to get diabetes care and estimated the difference based on our experiment, instrumenting going to CdA rather than to other providers by being in the treatment group. We winzorized at 5% the upper tail to omit implausible waiting times. Robust standard errors in parentheses. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.


Table 9: Effect on HbA1c by saturation for IMSS enrollees

	HbA1c IMSS Members	HbA1c non-IMSS-members
	(1)	(2)
Treatment	0.22 (0.37)	-0.17 (0.54)
High saturated clinic	0.88*** (0.31)	-0.15 (0.47)
Treat x High sat. Clinic	-0.85** (0.41)	0.05 (0.6)
Branch FE	Yes	Yes
IMSS only	Yes	No
Observations	515	292
R-squared	0.28	0.30

Notes: This table presents the heterogeneity results on the effect of CDA on HbA1c by saturation of IMSS clinics in Nuevo León. We define a clinic as saturated if they have at least an 85% flow of maximum capacity on average. That is, if they have at least 3.4 patients per hour per office open on average over a full year. The first column reports the heterogeneity estimates for IMSS population while the second column reports the same estimates for patients that do not report getting access to IMSS, which serves as a placebo. We control by HbA1c and branch fixed effects. We focus only in Nuevo León because Coahuila has very few IMSS clinics in Torreón and Saltillo, so we could not exploit the clinics heterogeneity there. Robust standard errors in parentheses. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.


Figures

Figure 1: Recruitment Process




Notes: This figure represents the process through which a patient was included in our experiment. The patient would first go through the regular free-screening that CDA usually offers and continue as a potential candidate unless she refused to fill out a survey. Then, if the patient was diagnosed as diabetic, the salesforce would try to sell a membership at full-price to that person. If the patient bought at full price, the person would leave the experiment, since we would know that person is an always taker. If the person was not interested in buying a full-price membership, then the salesforce would offer the chance to win a 60% discount from our study. This is the first point in which we would modify the regular flow of patients within CdA. If the person said they were not interested at that price either, then we would know that such a patient was a never taker. However, if the person said she was interested, then a button on the computer would reveal the treatment status to the salesforce and they would be able to offer the 60% discount if the patient was in the treatment group.

Figure 2: Recruitment Summary




Notes: This figure summarizes our 8 month recruitment results. We can see that there were nearly 8,000 diabetes patients that inquired about CDA, that our randomization was done evenly among treatment and control groups and that 94% of the patients were willing to answer our baseline survey. Moreover, we can see that through our deniers randomization design we were able to screen out 67% of the sample as always takers or never takers, which significantly increased our power for this experiment.

Figure 3: CATE: Compliers vs. Always Takers




Notes: This figure compares the distribution of the conditional average treatment effect we estimate based on [Athey and Wager \(2019\)](#) for our sample and how such an effect looks if we extrapolate to the rest of patients that showed interest in CdA. We can see both distributions look quite similar. Note that here we only utilize the reduced form estimates from being assigned to control or treatment and not the IV since we cannot know the endogenous choice that a regular patient would have made on whether or not to take up the offer by CdA. All the persons out of the experiment were assigned a zero in the treatment variable. We include as covariables: gender, HbA1c, BMI, age, social insurance and the clinic where the appointment took place. We omit the education variable because of missing values.

Figure 4: Savings from Hospitalizations Averted per Patient/Year (comparing T vs C)



Notes: This figure shows the savings we would observe from averted hospitalizations based on the reductions in HbA1c we causally estimate along with what the medical literature estimates and public spending data from the government. Specifically, we follow six steps. In six steps, recognizing the important heterogeneity in impacts by baseline blood sugar levels. First, we classify our sample into HbA1c baseline value bins, using the smaller nearest integer. Second, for those in the control group, in each bin we averaged their HbA1c observed at follow up ($HbA1C_{C_j}^{followup}$). Third, to go from HbA1c levels to health complications, we use the complications incidence tables by level of HbA1c from the widely cited UKPDS 35 study (King et al., 2001). This gives us the estimated complications for the control group by bin. Fourth, we apply an analogous method for the treatment group. We start from their baseline level and add in the conditional local average treatment effect (CLATE) of the respective bin, where the estimate is done as above but separately for each bin. That is for each bin j we calculate the number $HbA1C_{T_j}^{followup} = HbA1C_{T_j}^{baseline} + CLATE_j$, and map these to health complications. Fifth, we define averted hospitalizations as the difference expected hospitalizations between treatment and control group for each bin. Finally, to estimate the savings to the system from reduced hospitalizations, we multiply what each complication costs by the averted hospitalizations using the cost data from Barraza-Lloréns et al. (2015) for 2013 in Mexico updated for inflation. Overall, we see that on average 55% of the costs would be recuperated by averted hospitalizations and that CdA is a potential savings mechanism for the government for most complicated patients. It is important to note that this figure is not considering substitution away from public sector services nor externalities from emptier clinics.

Figure 5: Distance to Clinic Distribution



Notes: This figure shows the distribution in distance from home to the clinic for the IMSS patients we utilize in our regressions. We winzorized the distances higher than 100 km.

References

- AGUILAR, A., E. GUTIERREZ, AND E. SEIRA (2021): "The Effectiveness of Sin Food Taxes: Evidence from Mexico," *Forthcoming Journal of Health Economics*. [7]
- AJALA, O., P. ENGLISH, AND J. PINKNEY (2013): "Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes," *The American Journal of Clinical Nutrition*, 97. [5, 13]
- ALMOMENTO.MX (2015): "¿Inicia privatización del IMSS?" Last accessed 9 March 2021, <http://fmdiabetes.org/inicia-privatizacion-del-imss/>. [1]
- ARNOLD, L. W. AND Z. WANG (2014): "The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies," *Society for Biomedical Diabetes Research*, 11. [13]
- ATHEY, S. AND S. WAGER (2019): "Estimating Treatment Effects with Causal Forests: An Application," *arXiv: Methodology*. [15, 37]
- BARRAZA-LLORENS, M., V. J. G. BARRÓN, C. H. VIVEROS, F. J. P. GUZMÁN, AND E. CRABLE (2015): *Carga Económica de la Diabetes Mellitus en México, 2013*, Fundación Mexicana para la Salud, A.C. [1, 16, 17, 38]
- BASU, S., J. ANDREWS, S. KISHORE, PANJABI, AND D. STUCKLER (2012): "Comparative Performance of Private and Public Healthcare Systems in Low- and Middle-Income Countries: A Systematic Review," *PLOS MEDICINE*, 6. [4]
- CHANDRA, A., J. GRUBER, AND R. MCKNIGHT (2010): "Patient cost-sharing and hospitalization offsets in the elderly," *American Economic Review*, 100. [5]
- CLINIC, M. (2020): "Type 2 diabetes," Last accessed 9 March 2021, [https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/diagnosis-treatment/drc-20351199#:~:text=Metformin%20\(Fortamet%2C%20Glumetza%2C%20others,body%20uses%20insulin%20more%20effectively](https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/diagnosis-treatment/drc-20351199#:~:text=Metformin%20(Fortamet%2C%20Glumetza%2C%20others,body%20uses%20insulin%20more%20effectively.). [5]
- COLCHERO, M. A., J. A. RIVERA, B. M. POPKIN, AND S. WEN (2017): "Sustained consumer response: evidence from two-years after implementing the sugar sweetened beverage tax in Mexico," *Health Affairs*, 36. [7]
- DAS, J., A. HOLLA, V. DAS, M. MOHANAN, D. TABAK, AND B. CHAN (2012): "In Urban And Rural India, A Standardized Patient Study Showed Low Levels Of Provider Training And Huge Quality Gaps," *Health Affairs*, 31. [4]
- DAS, J., A. HOLLA, A. MOHPAL, AND K. MURALIDHARAN (2016): "Quality and Accountability in Health Care Delivery: Audit-Study Evidence from Primary Care in India," *American Economic Review*, 106. [4]
- FRAKES, M., J. GRUBER, AND A. JENA (2021): "Is great information good enough? Evidence from physicians as patients," *Journal Health Economics*, 75. [1]
- HEALD, A. H., M. STEDMAN, M. DAVIES, M. LIVINGSTON, R. ALSHAMES, M. LUNT, G. RAYMAN, AND R. GADSBY (2020): "Estimating life years lost to diabetes: outcomes from analysis of National Diabetes Audit and Office of National Statistics data," *Cardiovascular Endocrinology Metabolism*, 9. [14, 18]
- IDF (2019): *IDF Diabetes Atlas 9th Edition*, International Diabetes Federation. [5]
- IMSS (2013): "Modelo de prevención en diabetes mellitus (PREVENIMSS)," 5ta Conferencia Científica Anual sobre Síndrome Metabólico, <https://www.slideshare.net/sindromemetabolico/modelo-de-prevencion-en-diabetes-mellitus-prevenimss>. [20]
- (2018a): "IMSS atiende cada año a 2.7 millones de personas con diabetes," Last accessed 9 March 2021, <http://www.imss.gob.mx/prensa/archivo/201815/035#:~:text=Cada%20a%C3%B1o%20en%20las%20Unidades,social%20para%20modificar%20estilos%20de>. [2]
- (2018b): "Informe al Ejecutivo Federal y al Congreso de la Unión 2017-2018," . [6]
- (2020): "Informe al Ejecutivo Federal y al Congreso de la Unión sobre la Situación Financiera y los Riesgos del Instituto Mexicano del Seguro Social 2019-2020," . [2]
- INEGI (2017): "Encuesta Nacional de Empleo y Seguridad Social: Principales Resultados," Last accessed 10 March 2021, https://www.inegi.org.mx/contenidos/programas/eness/2017/doc/presentacion_eness_2017.pdf. [6]
- (2018): "Encuesta Nacional de Ingresos y Gastos de los Hogares," . [2]
- (2019a): "Cuenta satélite del Sector Salud de México, 2019," Last accessed 10 March 2021, <https://www.inegi.org.mx/temas/saludsat/>. [6]
- (2019b): "¿De qué mueren los mexicanos?" Last accessed 9 March 2021, <http://cuentame.inegi.org.mx/poblacion/defunciones.aspx?tema=P>. [1]
- INSP (2012): "Encuesta Nacional de Salud y Nutrición 2016," . [7]
- (2018): "Encuesta Nacional de Salud y Nutrición 2018," . [1, 2, 7]

- IQEHC (2007): “What are disease management programs (DMP’s)?” Last accessed 10 March 2021, [https://www.ncbi.nlm.nih.gov/books/NBK279412/#:~:text=Disease%20management%20programs%20\(DMPs\)%20are,called%20%E2%80%9Cstructured%20treatment%20programs.%E2%80%9D](https://www.ncbi.nlm.nih.gov/books/NBK279412/#:~:text=Disease%20management%20programs%20(DMPs)%20are,called%20%E2%80%9Cstructured%20treatment%20programs.%E2%80%9D). [8]
- ISMAIL, K., K. WINKLEY, AND S. RABE-HESKETH (2004): “Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes,” *The Lancet*, 363. [5, 13]
- JAGER, W. (2003): *Breaking ‘bad habits’: a dynamical perspective on habit formation and change*, University of Groningen. [14]
- KING, P., I. PEACOCK, AND R. DONNELLY (2001): “The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes,” *British Pharmacological Society Journals*. [13, 17, 38]
- LEE, C., G. CHERTOW, AND S. ZENIOS (2009): “An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard,” *American Economic Review*, 12. [19]
- NATHAN, D., J. KUENEN, R. BORG, H. ZHENG, D. SCHOENFELD, R. J. HEINE, AND A.-D. A. G. S. GROUP (2008): “Translating the A1C assay into estimated average glucose values,” *American Diabetes Association*. [21]
- NIDDK (2018): “The A1C Test & Diabetes,” Last accessed 9 March 2021, [https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test#:~:text=The%20A1C%20test%20measures%20the,level%20is%20below%205.7%20percent.https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test#:~:text=A%20hemoglobin%20A1c%20\(HbA1c\)%20test%20measures%20the%20amount%20of%20blood,the%20rest%20of%20your%20body](https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test#:~:text=The%20A1C%20test%20measures%20the,level%20is%20below%205.7%20percent.https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test#:~:text=A%20hemoglobin%20A1c%20(HbA1c)%20test%20measures%20the%20amount%20of%20blood,the%20rest%20of%20your%20body). [6]
- OECD (2019): “Diabetes Care,” Last accessed 10 March 2021, <https://www.oecd-ilibrary.org/sites/402e2e10-en/index.html?itemId=/content/component/402e2e10-en>. [1, 7]
- OJEDA, R. (2019): “Diabetes en México: así se comporta la segunda causa de muerte en el país,” Last accessed 10 March 2021, <https://www.milenio.com/ciencia-y-salud/diabetes-en-mexico-2020-estadisticas-y-porcentaje>. [7]
- PIMOUGUET, C., M. L. GOFF, R. THIÉBAUT, J. F. DARTIGUES, AND C. HELMER (2011a): “Effectiveness of disease-management programs for improving diabetes care: a meta-analysis,” *CMAJ-JAMC*, 183. [3]
- (2011b): “Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes,” *CMAJ*, 183. [5, 13]
- POLÍTICO, A. (2020): “México termina la Jornada de Sana Distancia en riesgo extremo, según el semáforo de Salud,” Last accessed 10 March 2021, <https://www.animalpolitico.com/2020/05/semaforo-retorno-apertura-nueva-normalidad-empresas-clases-educacion/>. [11]
- SAEEDI, P., I. PETERSOHN, P. SALPEA, B. MALANDA, AND S. KARURANGA (2019): “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition,” *Diabetes Research and Clinical Practice*, 157. [1, 5]
- SSP (2018): “Afiliación histórica del Sistema de Protección Social en Salud,” Last accessed 10 March 2021, <https://www.gob.mx/salud/seguropopular/documentos/afiliacion-historica-del-sistema-de-proteccion-social-en-salud#:~:text=A%20diciembre%20de%202018%2C%2053,la%20poblaci%C3%B3n%20total%20del%20pa%C3%ADs>. [6]
- (2021): “Catálogo de Clave Única de Establecimientos de Salud,” Last accessed 10 March 2021, http://www.dgis.salud.gob.mx/contenidos/intercambio/clues_gobmx.html. [2, 7]
- UMPIERRE, D., P. A. B. RIBEIRO, C. K. KRAMER, C. B. LEITÃO, A. T. N. ZUCATTI, M. J. AZEVEDO, J. L. GROSS, J. P. RIBEIRO, AND B. D. SCHAAN (2011): “Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis,” *JAMA*, 305. [5, 13]
- WHO (2021): “Mean fasting blood glucose,” Last accessed 9 March 2021, <https://www.who.int/data/gho/indicator-metadata-registry/imr-details/2380#:~:text=The%20expected%20values%20for%20normal,and%20monitoring%20glycemia%20are%20recommended>. [6]
- ÁNGEL RIVERA DOMMARCO, J., A. COLCHERO, M. L. FUENTES, T. G. DE COSÍO MARTÍNEZ, C. A. A. SALINAS, G. H. LICONA, AND S. BARQUERA (2018): *La Obesidad en Mexico Estado de la política pública y recomendaciones para su prevención y control*, INSP. [7]